What Is Low-Dose Naltrexone?
Low-dose naltrexone (LDN) refers to naltrexone used at doses of 1-5mg, much lower than the standard 50mg dose used for addiction. At these low doses, it's thought to have different effects that may help with pain and inflammation. It's an off-label use gaining interest for chronic pain conditions.1
How It May Work2
- Modulates the immune system
- Reduces glial cell activation in nervous system
- May decrease inflammation
- Temporarily blocks opioid receptors
- May increase endorphin production (rebound effect)
Conditions Being Studied
- Fibromyalgia (most research)
- Chronic fatigue syndrome
- Multiple sclerosis
- Crohn's disease
- Complex regional pain syndrome
- Rheumatoid arthritis
Evidence3
- Small studies show promise for fibromyalgia
- Some benefit seen in autoimmune conditions
- Research is still limited
- Large clinical trials needed
- Not FDA-approved for pain
Dosing
- Typically 1.5-4.5mg daily
- Usually taken at bedtime
- Often started low and increased gradually
- Requires compounding pharmacy
- Regular naltrexone tablets are 50mg
Side Effects
- Generally well-tolerated
- Vivid dreams (common)
- Sleep disturbances (usually temporary)
- Nausea
- Headache
- Most side effects diminish over time
Important Considerations
- Cannot take with opioid medications
- Must stop opioids before starting LDN
- Not covered by most insurance
- Requires compounding (cost varies)
- Many doctors unfamiliar with LDN
Finding LDN
- Requires prescription
- Need compounding pharmacy
- Some integrative medicine doctors prescribe
- Ask if your doctor is familiar with LDN research
References
- Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459.
- Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663-672.
- Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382-389.